Acorda Therapeutics Inc. (NASDAQ:ACOR)’s share price traded up 6.6% during trading on Wednesday . The stock traded as high as $26.02 and last traded at $25.89, with a volume of 422,119 shares changing hands. The stock had previously closed at $24.29.

Several equities analysts have recently commented on the company. Cowen and Company reiterated a “buy” rating on shares of Acorda Therapeutics in a research note on Sunday, April 17th. Aegis increased their target price on Acorda Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday, June 1st. Leerink Swann reiterated a “hold” rating and set a $29.00 target price (down from $31.00) on shares of Acorda Therapeutics in a research note on Sunday, May 22nd. Zacks Investment Research cut Acorda Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 28th. Finally, Evercore ISI restated a “hold” rating and set a $32.00 price objective on shares of Acorda Therapeutics in a research note on Friday, May 20th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $38.67.

The company has a market cap of $1.17 billion and a PE ratio of 84.14. The firm has a 50 day moving average of $26.04 and a 200 day moving average of $30.22.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.01. During the same quarter last year, the firm earned $0.15 earnings per share. The company earned $115.90 million during the quarter, compared to analyst estimates of $115.36 million. The business’s quarterly revenue was up 16.1% compared to the same quarter last year. On average, equities research analysts anticipate that Acorda Therapeutics Inc. will post $0.75 EPS for the current fiscal year.

In other Acorda Therapeutics news, insider Andrew A. Hindman sold 4,860 shares of Acorda Therapeutics stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $26.11, for a total value of $126,894.60. Following the transaction, the insider now directly owns 49,670 shares of the company’s stock, valued at approximately $1,296,883.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Steven M. Rauscher sold 1,086 shares of Acorda Therapeutics stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $27.83, for a total value of $30,223.38. Following the completion of the transaction, the director now directly owns 1,086 shares in the company, valued at $30,223.38. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have modified their holdings of the company. State of Tennessee Treasury Department acquired a new position in shares of Acorda Therapeutics during the fourth quarter valued at approximately $1,425,000. Jennison Associates LLC acquired a new position in shares of Acorda Therapeutics during the fourth quarter valued at approximately $14,201,000. Whittier Trust Co. increased its position in shares of Acorda Therapeutics by 1.1% in the fourth quarter. Whittier Trust Co. now owns 33,107 shares of the biopharmaceutical company’s stock valued at $1,416,000 after buying an additional 346 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Acorda Therapeutics by 8.1% in the fourth quarter. Principal Financial Group Inc. now owns 291,640 shares of the biopharmaceutical company’s stock valued at $12,476,000 after buying an additional 21,838 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Acorda Therapeutics by 1.1% in the fourth quarter. New York State Common Retirement Fund now owns 149,231 shares of the biopharmaceutical company’s stock valued at $6,384,000 after buying an additional 1,565 shares in the last quarter.

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.